Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: FirstWord Group | PRODUCT CODE: 1796158

Cover Image

PUBLISHER: FirstWord Group | PRODUCT CODE: 1796158

Rx Barriers (US) - Schizophrenia

PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Multi User License (PDF)
USD 8000

Add to Cart

This report examines how external market barriers influence prescribing decisions in the schizophrenia market. Drawing on survey data from treating physicians, it analyzes factors such as cost, availability, reimbursement, guidelines, and patient preferences, and their impact on therapy choice. The findings provide a detailed view of who is and is not prescribing specific brands, how barriers shape prescription patterns, and the resulting shifts in market share between competing therapies.

Key Questions Answered:

  • 1. How are external factors such as cost, availability, and patient preferences impacting your brand's market share?
  • 2. Who is and isn't prescribing your brand, and which physicians are willing to consider it?
  • 3. How do physicians choose therapies and which barriers significantly influence their decisions?
  • 4. How much market share does your brand gain or lose due to various barriers and who are the key competitors?

Key Brands:

  • Abilify (aripiprazole)
  • Abilify Asimtufii (aripiprazole)
  • Abilify Maintena (aripiprazole)
  • Caplyta (lumateperone)
  • Clozaril (clozapine)
  • Cobenfy (trospium chloride/xanomeline)
  • Invega (paliperidone)
  • Invega Sustenna (paliperidone palmitate)
  • Latuda (lurasidone)
  • Lybalvi (olanzapine/samidorphan)
  • Risperdal (risperidone)
  • Vraylar (cariprazine)
  • Zyprexa (olanzapine)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!